Tesamorelin is the only FDA-approved GHRH analog, a 44-amino-acid copy of human growth-hormone-releasing hormone with a stabilizing trans-3-hexenoic acid group. It's approved (as Egrifta / Egrifta SV) for reducing excess belly fat in HIV-associated lipodystrophy.
Tesamorelin + Ipamorelin Prices
2 vendors · 2 with an issuer-verified COA · 10mg buy-in from $85.00 · checked
Where to buy Tesamorelin + Ipamorelin: 2 vendors compared
2 of 2 vendors
| Vendor | Price | Updated | Actions |
|---|---|---|---|
| 8-test panelVerified COAFreedom Diagnostics | $85.00Reader code pending·auto20mg packageChecked Oct 6, 2026 | Oct 6, 2026 | Buy Tesamorelin + Ipamorelin from Novaglo Research |
| 5-test panelVerified COAKovera Labs · Tested Oct 1, 2026 | $85.46 | Oct 5, 2026 | Buy Tesamorelin + Ipamorelin from Zen Aminos |
Tracked every day
Tesamorelin + Ipamorelin price per mg, tracked daily
The five cheapest in-stock listings for Tesamorelin + Ipamorelin on each collected day, and the vendors that most often held those places.
Five cheapest in-stock listings per day
- Cheapest$94.95
Vendors most often in the cheapest five
- Zen Aminos2 days$94.950.0%
Current market data
Tesamorelin + Ipamorelin Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Tesamorelin + Ipamorelin is $85.00 from Novaglo Research. The median across vendors is $85.23.
- Lowest 10mg cost
- $85.00Novaglo Research
- Median 10mg cost
- $85.23One normalized offer per vendor
- Lowest package total
- $85.00Novaglo Research · package size may differ
- Public COA coverage
- 100%2 of 2 vendors
What the market shows
PeptidePrices found 2 in-stock listings from 2 vendors, checked through Oct 6, 2026. The lowest 10mg cost is 0% below the vendor median of $85.23; 1 vendors (50%) fall below that median. 2 of 2 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Tesamorelin + Ipamorelin? Research, safety, and status
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), developed by Theratechnologies and FDA-approved for reducing the excess visceral fat that often accompanies HIV lipodystrophy (a fat-redistribution problem linked to antiretroviral therapy). It's the only GHRH analog with full FDA approval, relatives like CJC-1295 and sermorelin are used off-label.
What makes it interesting beyond its label: instead of adding external growth hormone, it stimulates your own pituitary to make more, keeping GH's natural pulsing rhythm intact. That gives it a genuinely strong clinical-evidence base, and it's why this monograph leans on real trial data rather than the 'preclinical/anecdotal' hedging most research peptides require. Still, off-label use (anti-aging, body recomp) hasn't been through the same regulatory scrutiny. Everything below is research context, not medical advice.
Key research takeaways
Its standout, well-documented effect is visceral (deep abdominal) fat reduction, Phase III trials showed roughly 15-18% VAT reduction by CT scan over 26 weeks. Stopping treatment reverses it, so benefits depend on continued use.
It has by far the strongest evidence base of the common research peptides, multiple Phase III trials, 52-week extensions, plus emerging cognition (executive function/verbal memory) and NAFLD liver-fat data.
It is prescription-only (off-label body-composition use is legal but unstudied), banned by WADA under S2, and carries a real glucose-intolerance signal, diabetes risk was ~3.3× placebo in trials.
Tesamorelin + Ipamorelin at a glance
PeptidePrices safety rating
8/10 · FDA-approved (Egrifta)
Mechanism
Research blend of the named components; compare total nominal mass and verify each component against the batch report.
Approved for HIV lipodystrophy; injection site reactions; fluid retention; well-characterized Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Related pages